The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on  March 11, 2016 for Hospira HealthCare Corporation’s subsequent entry biologic (SEB), INFLECTRA™ (infliximab).

According to the CADTH website, Hospira is seeking public reimbursement for Crohn’s disease and Ulcerative Colitis.

For those interested in providing patient input, please complete the CDR Patient Input Submission. CADTH’s Common Drug Review (CDR) deadline for patient input for INFLECTRA is May 2, 2016.

For more information, please visit the CADTH website.